Evaxion A (EVAX) Total Non-Current Liabilities (2021 - 2025)
Evaxion A (EVAX) reported Total Non-Current Liabilities of $7.1 million for Q4 2025, down 27.2% on a YoY basis from $9.8 million in Q4 2024, and down 34.76% quarter-over-quarter from $10.9 million in Q2 2025.
Evaxion A (EVAX) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Evaxion A has reported Total Non-Current Liabilities for 5 years, with the latest figure at $7.1 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 27.2% year-over-year to $7.1 million; the trailing twelve-month figure through Dec 2025 stood at $7.1 million (down 27.2% YoY), and the FY2025 full-year result was $7.1 million, down 27.2% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $7.1 million, down from $10.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $10.9 million in Q2 2025, with the low at $1.0 million in Q2 2021.
- Historically, Total Non-Current Liabilities has averaged $7.5 million across 5 years, with a median of $9.8 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 819.77% — and 2025, when it declined 27.2%.
- Evaxion A's Total Non-Current Liabilities stood at $3.4 million in 2021, then jumped by 192.68% to $10.0 million in 2022, then increased by 5.76% to $10.5 million in 2023, then slipped by 7.26% to $9.8 million in 2024, then retreated by 27.2% to $7.1 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $7.1 million (Q4 2025), $10.9 million (Q2 2025), and $9.8 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 7.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.11 Mn |
| Jun 30, 2025 | 10.90 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Jun 30, 2024 | 10.16 Mn |
| Dec 31, 2023 | 10.53 Mn |
| Jun 30, 2023 | 10.17 Mn |
| Dec 31, 2022 | 9.96 Mn |
| Jun 30, 2022 | 9.45 Mn |
| Mar 31, 2022 | 10.01 Mn |
| Dec 31, 2021 | 3.40 Mn |
| Sep 30, 2021 | 3.54 Mn |
| Jun 30, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.11 Mn |